arrow_back Back to App

Support for Serious Infection Drugs: New Rules for Biological Products

This act aims to accelerate access to new drugs and biological products that combat serious and life-threatening infections, including antibiotic-resistant ones. This means citizens can receive innovative therapies faster, increasing the chances of effective treatment for difficult diseases.
Key points
Expands the definition of "qualified infectious disease products" to include biological products, meaning more support for their development.
Allows for faster review and approval by regulatory bodies of drugs and biological products intended to combat serious infections.
Focuses on drugs that fight bacteria and fungi, including those resistant to existing therapies, which is crucial for public health.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_3478
Sponsor: Sen. Casey, Robert P., Jr. [D-PA]
Process start date: 2022-01-11
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

GAIN TOOLS Act of 2022

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_3478.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2022-01-11.

What are the main provisions?

Key points include:

  • Expands the definition of "qualified infectious disease products" to include biological products, meaning more support for their development.
  • Allows for faster review and approval by regulatory bodies of drugs and biological products intended to combat serious infections.
  • Focuses on drugs that fight bacteria and fungi, including those resistant to existing therapies, which is crucial for public health.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Casey, Robert P., Jr. [D-PA].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2026-01-02.

CATEGORIES

Health